MAA868 locks factor XIa in a zymogen-like state

Abstract

In this issue of Blood, Koch et al show that MAA868, a novel humanized monoclonal antibody that locks activated factor XI (FXIa) in a zymogen-like state, produces long-lasting antithrombotic effects without disrupting hemostasis. 1 If these preclinical and phase 1 findings can be replicated in clinical trials, MAA868 and other FXI-directed anticoagulant strategies have the potential to change practice by offering safer anticoagulant therapy to tackle the burden of thrombosis.